IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

VIGANO', MAURO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7107
NA - Nord America 3283
AS - Asia 1549
SA - Sud America 89
AF - Africa 21
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 7
Totale 12066
Salva come PNG Salva come JPEG
Nazione #
GB - Regno Unito 3585
US - Stati Uniti d'America 3200
CN - Cina 926
IT - Italia 700
DE - Germania 697
SE - Svezia 637
UA - Ucraina 338
FR - Francia 262
IE - Irlanda 195
TR - Turchia 193
RU - Federazione Russa 177
KR - Corea 171
EU - Europa 130
IN - India 125
NL - Olanda 97
PL - Polonia 95
FI - Finlandia 94
DK - Danimarca 82
CA - Canada 81
CO - Colombia 73
BE - Belgio 53
GR - Grecia 52
VN - Vietnam 35
ID - Indonesia 23
HK - Hong Kong 16
JP - Giappone 16
UZ - Uzbekistan 13
ES - Italia 11
CH - Svizzera 10
BR - Brasile 8
AU - Australia 7
RO - Romania 6
TH - Thailandia 6
PT - Portogallo 5
DZ - Algeria 4
IR - Iran 4
MY - Malesia 4
PH - Filippine 4
RS - Serbia 4
AR - Argentina 3
AT - Austria 3
EG - Egitto 3
ET - Etiopia 3
BD - Bangladesh 2
CZ - Repubblica Ceca 2
MA - Marocco 2
MX - Messico 2
PE - Perù 2
SA - Arabia Saudita 2
SG - Singapore 2
TN - Tunisia 2
TW - Taiwan 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AP - ???statistics.table.value.countryCode.AP??? 1
BG - Bulgaria 1
BY - Bielorussia 1
CL - Cile 1
GH - Ghana 1
IL - Israele 1
IQ - Iraq 1
KE - Kenya 1
LB - Libano 1
LY - Libia 1
NG - Nigeria 1
PS - Palestinian Territory 1
SC - Seychelles 1
SD - Sudan 1
SN - Senegal 1
Totale 12187
Salva come PNG Salva come JPEG
Città #
Southend 3430
Chandler 619
Seattle 309
Jacksonville 298
Milan 260
Beijing 245
Princeton 232
Dublin 182
Wilmington 175
Ann Arbor 153
Nanjing 139
Mountain View 131
Dearborn 115
Redmond 115
Serra 90
Warsaw 90
Andover 80
Fairfield 80
Sakarya 79
Boardman 78
Des Moines 75
Toronto 72
Bogotá 71
Woodbridge 64
Somerville 56
Brussels 50
Ashburn 46
Jinan 45
Hebei 44
Shenyang 44
Athens 39
Grafing 37
Nanchang 35
Phoenix 33
Saint Petersburg 33
Houston 30
Tianjin 30
Kiez 26
Redwood City 26
Shanghai 24
Bitonto 23
Guangzhou 21
Turin 21
Hangzhou 20
Zhengzhou 19
Nürnberg 18
Changsha 17
Mumbai 17
Fremont 16
San Diego 16
Berlin 15
Kunming 15
Munich 15
Menlo Park 14
Central District 13
Hanoi 13
Hefei 12
Jiaxing 12
Los Angeles 12
Palaiseau 12
Roxbury 11
Scranton 11
Auburn Hills 10
Lanzhou 10
Levico Terme 10
Palermo 10
Cambridge 9
Dong Ket 9
Ningbo 9
Rome 9
Boise 8
Hanover 8
Pskov 8
Verona 8
Chengdu 7
New York 7
San Sperate 7
Seoul 7
Chicago 6
Costa Mesa 6
Gussago 6
London 6
Odernheim 6
Ottawa 6
Sunnyvale 6
Chongqing 5
Haikou 5
Hamburg 5
Seocho 5
Tokyo 5
Birmingham 4
Lissone 4
Madrid 4
Margão 4
Petina 4
Sarroch 4
Shenzhen 4
Svilajnac 4
Taizhou 4
Ankara 3
Totale 8365
Salva come PNG Salva come JPEG
Nome #
Maintained long-term suppression of HBV replication in NUC-naïve patients with chronic hepatitis B treated with ETV monotherapy in field practice : the Italian multicenter experience 327
Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B from field practice : high efficacy and favorable safety profile over 3 years of treatment 241
Low rates of genotypic resistance to adefovir in lamivudine resistant patients treated with adefovir-lamivudine combination therapy for 3 years 218
Combined lamivudine and adefovir dipivoxil treatment allows safe and long-term compath-1H therapy in refractory B-cell chronic lymphocytic leukemia with HBV reactivation 210
Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis 204
A response guided approach to peginterferon alfa-2a therapy based on HBsAg levels at weeks 12 and 24 improves response rates in HBeAG-negative, genotype D chronic hepatitis B patients 198
3 years of Adefovir and Lamivudine combination therapy minimized the risk of genotypic resistance to ADV in Lam resistant patients 183
3 years of Adefovir and Lamivudine combination therapy minimized the risk of genotypic resistance to ADV in Lam resistant patients 178
Accuracy of two new predictive models in assessing fibrosis in chronic hepatitis C (CHC) 177
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistant patients with HBeAg-negative chronic hepatitis B 174
Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H 167
US features of liver surface nodularity as a predictor of severe fibrosis in chronic hepatitis C 164
Real life experiences in HCV management in 2018 164
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistano patients with HBeAg-negative chronic hepatitis B 161
Anemia during peginterferon-ribavirin therapy results from both increased suppression of erythroid differentiation and haemolysis 160
Versant 3.0 and Cobas Taqman for monitoring serum HBV-DNA in HBeAg-negative patients under lamivudine-adefovir combinant therapy 157
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegykated interferon-α2A in chronic hepatitis C : an in vitro and in vivo study 156
Versant 3.0 and Cobas Taqman for monitoring serum HBV-DNA in HBeAg-negative patients under lamivudine-adefovir combinant therapy 156
Combination therapy with adefovir dipivoxil (ADV)and lamivudine (LAM) in LAM-resistant patients enlisted for liver transplantation 155
Inhibition of HBV-replication by combined treatment of lamivudine and adefovir dipivoxil allows long-term campath-1H therapy in refractory B-cell chronic lymphoblastic leukemia 152
Natural history of HCC developing in HBV-related cirrhotic patients undergoing antiviral treatment with nucleos(t)ide analogues 151
Very early add-on adefovir therapy in patients with sub-optimal virological response to lamivudine 151
Severe hepatic fibrosis in chronic hepatitis C 150
PegBeLiver study : HBsAg decline at week 24 of extended Peginterferon Alfa-2A (PEG-IFNα-2a) therapy is significantly associated with post-treatment response in HBeAg-negative genotype D patients 150
High risk of renal impairment and arterial hypertension during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 149
Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis 145
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 144
Clinical implications of HBsAg quantification in patients with chronic hepatitis B 144
Five years of sequential lam to lam_adv therapy suppresses HBV replication in most hbeag-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma 141
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine 139
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudineresistant chronic hepatitis B 138
Excellent 5-year overall survival in patients with HBV-related cirrhosis undergoing liver transplantation for hepatocellular carcinoma 138
Six years of “on demand” LAM ± ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with HBeAg-negative cirrhosis 137
Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants 134
Effectiveness of Entecavir for the treatment of NUC-naïve chronic hepatitis B patients : a large multicenter cohort study in clinical practice 134
Evaluating liver fibrosis in chronic hepatitis c (CHC), accuracy of two new predictive models 133
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegylated interferon-alpha 2a in chronic hepatitis C : an in vitro and in vivo study 132
Add on Adefovir prevents the emergence of ADV resistance in Lamivudine-resistant patients : a 4-year study 132
Effectiveness of entecavir for the treatment of nuc-naïve chronic hepatitis B patients : a large multicenter cohort study in clinical practice 130
Entecavir is an effective treatment for NUC-naive chronic hepatitis B patients in clinical practice : 48-week data from a large multicenter cohort study 130
Entecavir for nuc-naïve chronic hepatitis B patients in clinical practice : long-term effectiveness from a large multicenter cohort study in 376 patients 130
Low risk of hepatitis B reactivation in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 129
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine 129
Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies : two case reports 128
Ruolo delle crioglobuline sieriche nel corso dell'epatopatia cronica HCV-correlata. Studio prospettico di coorte di 343 pazienti 127
Four years of Adefovir add-on in 145 lamivudine resistant patients with chronic hepatitis B : low risk of genotypic resistance to ADV and prevention of virologic breakthrough 127
Transient elastography (TE) accurately predicts liver fibrosis stage in patients with chronic hepatitis B 126
Evaluation of three “beyond Baveno VI” criteria to safely spare endoscopies in compensated advanced chronic liver disease 124
Effectiveness of entecavir for the treatment of NUC-naïve chronic hepatitis B patients : A large multicenter cohort study in clinical practice 122
No evidence for ADV resistance in HBeAg negative lamivudine resisstant patients treated with lamivudine-adefovir combination for 3 years 120
Changes in liver stiffness during entecavir therapy in patients with chronic hepatitis B 120
No evidence for ADV resistance in HBeAg-negative Lamivudine resistant patients treated with LAMIVUDINE-ADEFOVIR combination for 3 years 118
The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis 118
Low risk of hepatitis B reactivatioin in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 118
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices : a 12-year prospective cohort study 118
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 117
Hepatitis B virus reverse seroconversion in allogeneic hematopoietic stem cell transplantation 116
Protocol liver biopsies to evaluate severity of recurrent HCV hepatitis : a recent monocentric experience 116
Six years of on demand LAM +/- ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with hbeag-negative cirrhosis 116
Changes in liver stiffness during entecavir therapy in patients with chronic hepatitis B 115
Entecavir for nuc-naïve chronic hepatitis b patients in clinical practice : long-term effectiveness from a large multicenter cohort study in 376 patients 115
Acute hepatitis following assumption of a herbal remedy 114
Transient elastography predicts response to prolonged therapy with a nucleoside analog in patients with chronic hepatitis B 112
Failure of adefovir 20 mg to improve suboptimal response in lamivudine resistant hepatitis B patients treated with adefovir 10 mg and lamivudine 111
Efficacy and safety of pegylated interferon plus ribavirin in patients with hepatitis C recurrence after liver transplantation : a single centre experience 109
Low resistance to adefovir combined with lamivudine : a 3-year study of 145 lamivudine-resistant hepatitis B patients 109
Prospective evaluation of staging systems for hepatocellular carcinoma detected during surveillance of cirrhotic patients 105
Natural history and clinical impact of cryoglobulins in chronic hepatitis C : 10-year prospective study of 343 patients 104
IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients 101
The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin 100
Lamivudine prophylaxis of hepatitis B reactivation in anti-HBC seroposivive patients undergoing chemotherapy for onco-hematological diseases 100
Graft dysfunction (GD) in HBV recurrence free recipience is associated with serum autoantibodies reactivity 99
Low risk of hepatocellular carcinoma recurrence after liver transplantation : a 3-year follow-up study in 78 patients with chronic hepatitis B 96
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegylated interferon-α2a in chronic hepatitis C: an in vitro and in vivo study 95
Late graft dysfunction (GD) in HBV recurrence-free recipients is associated with serum antinuclear antibodies (ANA) reactivity 94
A non-invasive algorithm accurately predicts advanced fibrosis in hepatitis C : a comparison using histology with internal-external validation 92
Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma 91
Six years of "on demand" LAM plus ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with HBeAg-negative cirrhosis 90
Progressive decline of HBsAg titers in longterm virological responders to nucleos(t)ide analogue therapy for chronic hepatitis B 90
Maintained HBV suppression in lamivudine-resistant patients treated with adefovir and lamivudine combination : A 4- year cohort study in 63 patients 89
Outbreak of Acute Hepatitis A involving young men in Lombardy region, Italy: Risk factors, clinical and virological characteristics 89
Safety and tolerability of extended (96 weeks) treatment with peginterferon alfa-2a [40kd] in genotype D patients with HBeAg-negative chronic hepatitis B 86
Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal 86
Progressive decline of HBsAg titers in long-term virological responders to nucleos(t)ide analogue therapy for chronic hepatitis B 84
Hepatocellular carcinoma in patients with compensated HCV-related cirrhosis responding to interferon : A 5-year follow-up study 84
PegIFN-α2a for the treatment of chronic hepatitis B and C : a 10-year history 84
Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B 83
High rates of hepatitis B virus riverse seroconversion in anti-HBc carriers undergoing allogeneic bone marrow transplantation 80
HBV and HCV Therapy 79
Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma 75
Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection 74
Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs) 74
Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy 69
AISF position paper on HCV in immunocompromised patients 69
Systematic review with meta-analysis : do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection? 67
Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon? 66
Low risk of hepatitis B virus reactivation in HBsAg-negative/anti-HBc-positive carriers receiving rituximab for rheumatoid arthritis : a retrospective multicenter Italian study 65
Review article : The potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection 63
Efficacy and safety of pegylated interferon plus ribavirin in patients with hepatitis C recurrence after liver transplantation : a single centre experience 62
null 61
Totale 12454
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20588
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20588
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/2018298 0000 00 00 00196102
2018/20191429 3449949161 17141 19437 1141118874
2019/20201742 2334673172 84186 155130 33417211641
2020/20211825 9812715331 129111 114134 21387412216
2021/20221426 127797394 6266 121121 13121081261
2022/20231775 231224144252 195351 3791 18133360
Totale 12964